1 results match your criteria: "IRCCS-CROB Referral Cancer Center of Basilicata Rionero in Vulture (PZ)[Affiliation]"
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
Future Oncol
July 2019
Laboratory of Preclinical & Translational Research, IRCCS-CROB Referral Cancer Center of Basilicata Rionero in Vulture (PZ), via Padre Pio 1, 85028, Italy.
At present three immune checkpoint inhibitors (ICIs), two anti-PD-1 (nivolumab and pembrolizumab) and one anti-PD-L1 (atezolizumab) can be used in pretreated non-small-cell lung cancer patients. The aim of this meta-analysis is an indirect comparison between anti-PD-1 and anti-PD-L1 inhibitors. Seven studies (>4000 patients) were considered.
View Article and Find Full Text PDF